Braun David A, Wu Catherine J
From the *Department of Medical Oncology, Dana-Farber Cancer Institute; †Department of Medicine, Brigham and Women's Hospital, Harvard Medical School; and ‡Massachusetts General Hospital Cancer Center, Boston; and §Broad Institute of MIT and Harvard, Cambridge, MA.
Cancer J. 2017 Mar/Apr;23(2):115-124. doi: 10.1097/PPO.0000000000000257.
Historically, immune-based therapies have played a leading role in the treatment of hematologic malignancies, with the efficacy of stem cell transplantation largely attributable to donor immunity against malignant cells. As new and more targeted immunotherapies have developed, their role in the treatment of hematologic malignancies is evolving and expanding. Herein, we discuss approaches for antigen discovery and review known and novel tumor antigens in hematologic malignancies. We further explore the role of established and investigational immunotherapies in hematologic malignancies, with a focus on personalization of treatment modalities such as cancer vaccines and adoptive cell therapy. Finally, we identify areas of active investigation and development. Immunotherapy is at an exciting crossroads for the treatment of hematologic malignancies, with further investigation aimed at producing effective, targeted immune therapies that maximize antitumor effects while minimizing toxicity.
从历史上看，基于免疫的疗法在血液系统恶性肿瘤的治疗中发挥了主导作用，干细胞移植的疗效很大程度上归因于供体对恶性细胞的免疫作用。随着更新、更具针对性的免疫疗法的发展，它们在血液系统恶性肿瘤治疗中的作用正在不断演变和扩大。在此，我们讨论抗原发现的方法，并回顾血液系统恶性肿瘤中已知和新发现的肿瘤抗原。我们进一步探讨既定和正在研究的免疫疗法在血液系统恶性肿瘤中的作用，重点关注癌症疫苗和过继性细胞疗法等治疗方式的个性化。最后，我们确定了积极研究和开发的领域。免疫疗法正处于血液系统恶性肿瘤治疗令人兴奋的十字路口，进一步的研究旨在开发有效的、有针对性的免疫疗法，在将毒性降至最低的同时最大化抗肿瘤效果。
